Attached files

                                  EXHIBIT 10(m)




                        FIRST AMENDMENT TO DEVELOPMENT,
                        SUPPLY AND DISTRIBUTION AGREEMENT


      THIS FIRST AMENDMENT TO DEVELOPMENT, SUPPLY AND DISTRIBUTION AGREEMENT
("First Amendment"), is made and dated as of October 31, 2008 (the Effective
Date), between CEL-SCI Corporation, a Colorado, USA, company ("CEL-SCI"), and
Orient Europharma Co. Ltd., a corporation organized and existing under the laws
of Taiwan, R.O.C., ("Orient Europharma"), with reference to the following facts:

A. CEL-SCI and Orient Europharma entered into that certain Development, Supply
and Distribution Agreement, dated November 10, 2000 ("DEVELOPMENT, SUPPLY AND
DISTRIBUTION AGREEMENT"). Except as otherwise modified in this First Amendment,
defined terms used herein shall have the same meanings given to them in the
Development, Supply and Distribution Agreement.

B. CEL-SCI and Orient Europharma now desire to amend the Development, Supply and
Distribution Agreement as set forth in this First Amendment.

      THEREFORE, for valuable consideration, the receipt and adequacy of which
are hereby acknowledged, CEL-SCI and Orient Europharma hereby agree to amend the
Development, Supply and Distribution Agreement as follows:

     1. Modifications to Development, Supply and Distribution Agreement.

          (a)  Definitions.  Section 1. m.  relating  to the  definition  of the
               territories  covered in the Development,  Supply and Distribution
               Agreement is deleted and the  following  language is  substituted
               therefore:

           1. m. "Territory shall mean Taiwan, Singapore, Malaysia, Hong
                  Kong, The Philippines, South Korea, Australia and New Zealand.
                  CEL-SCI grants to Orient Europharma the first right of
                  negotiation with respect to country-regionThailand and
                  placecountry-regionChina."

     2.   As valuable  consideration  for this amendment Orient  Europharma
          agrees  to  purchase  $500,000  worth  of  CEL-SCI  common  stock
          directly  from  CEL-SCI  within  one week of  signing  this First
          Amendment. The price of the stock to be paid by Orient Europharma
          will be the average of the CEL-SCI  common stock  closing  prices
          listed on Yahoo  Finance of the 30  trading  days  preceding  the
          Effective Date of this First Amendment.

     3.   CEL-SCI and Orient Europharma confirm that Orient Europharma will
          be responsible for * of the costs of CEL-SCI's  advanced  primary
          head and neck cancer Phase III trial with  Multikine  approved by
          the FDA.

* Confidential treatment requested. Confidential portion has been omitted and
filed separately with the Securities and Exchange Commission.




     4.   Neither party shall publish  financial details related to revenue
          sharing and Orient  Europharma's  participation  in the Phase III
          clinical trial covered in the First Amendment to the Development,
          Supply and  Distribution  Agreement and, as far as possible,  the
          November 10, 2000 Agreement.  Notwithstanding the foregoing, each
          party may disclose the existence  and terms of this  Agreement as
          necessary   for  filings  with  the  U.S.   Securities   Exchange
          Commission  or  a  nationally   recognized  securities  exchange;
          provided,  that  such  party  informs  the other  party  prior to
          publication.

     5.   Conflicts.  If any conflict  between this First Amendment and the
          Development,  Supply and Distribution Agreement should arise, the
          terms of this First Amendment shall control.

     6.   Successor and Assigns. This First Amendment shall be binding upon
          and inure to the  benefit of the  successors  and  assigns of the
          respective parties hereto.

     7.   Counterparts.  This First  Amendment  may be executed in multiple
          counterparts,  each of which shall be deemed an original, but all
          of which shall together constitute a single instrument.

     The parties have executed this First Amendment as of the date first written
above.

CEL-SCI:                                ORIENT EUROPHARMA:

CEL-SCI Corporation,                     Orient Europharma Co. Ltd.,
a Colorado, USA, company                 a Taiwanese corporation

By:    /s/ Geert R. Kersten             By:    /s/ H.T. Stiftl
       ------------------------------          -------------------------------

Name:  Geert R. Kersten                 Name:  H.T. Stiftl
       ------------------------------          -------------------------------

Title: Chief Executive Officer          Title: Managing Director
       ---------------------------             -------------------------------


                                       3